Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Limustin®, a non-innovator tacrolimus formulation, yields reduced drug exposure in pediatric renal transplant recipients.

Pediatric transplantation - 1 Nov 2014

Jacobo-Cabral Carlos O, García-Roca Pilar, Reyes Herlinda, Lozada-Rojas Lucero, Cruz-Antonio Leticia, Medeiros Mara, Castañeda-Hernandez Gilberto

Abstract excerpt

The aim of this study was to evaluate the bioavailability of two oral tacrolimus formulations, the innovator Prograf(®) and a formulation commercialized in Mexico with the brand name Limustin(®), in children. Stable Mexican pediatric renal transplant recipients received the product authorized by their social security provider, being either Prograf(®) or Limustin(®). At steady state, blood samples were drawn and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Area Under Curve

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Drug Administration Schedule

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Mexico

Share to Tacrolimus

Source

Identifiers

PMID: 25156476
DOI: 10.1111/petr.12335

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Limustin®, a non-innovator tacrolimus formulation, yields reduced drug exposure in pediatric renal transplant recipients.PMID 25156476Read ↗

Population pharmacokinetic analysis of tacrolimus in Mexican paediatric renal transplant patients: role of CYP3A5 genotype and formulation.Semantic proximity Read ↗

Conversion from Prograf to Advagraf in adolescents with stable liver transplants: comparative pharmacokinetics and 1-year follow-up.Semantic proximity Read ↗

Tacrolimus Pharmacokinetic and Pharmacogenomic Differences between Adults and Pediatric Solid Organ Transplant RecipientsSemantic proximity Read ↗

Tacrolimus Conversion in CYP3A5*1 Expressers: From Immediate-Release to LCP Formulation.Semantic proximity Read ↗

Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant RecipientsSemantic proximity Read ↗

Effect of <em>CYP3A5</em> Polymorphism on Liver Function and Tacrolimus Pharmacokinetics after Conversion to a Once-Daily Tacrolimus Formulation in Stable Liver Transplant PatientsSemantic proximity Read ↗

Dose tailoring of tacrolimus based on a non-linear pharmacokinetic model in children with refractory nephrotic syndrome.Semantic proximity Read ↗

Prograf produces more benefits for CYP3A5 low expression patients in early stage after kidney transplantation.Semantic proximity Read ↗

Initial dose optimization of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism and coadministration with Wuzhi capsule.Semantic proximity Read ↗

How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation.Semantic proximity Read ↗

Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients.Semantic proximity Read ↗

Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.